392661-17-5

Name	L-α-Glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginylglycine
CAS	392661-17-5
Molecular Formula	C164H255N47O37S
Molecular Weight	3509.14
MOL File	392661-17-5.mol

Synonyms

L-α-Glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginylglycine

show less show more

Chemical Properties

density

1.44±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

Hazard Information

Uses

PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2].

in vivo

PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo^[1].
PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor ^[1].

Animal Model:	Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)^[1]
Dosage:	2 mg/mouse
Administration:	Implanted s.c. or i.p., with 14 days mini-osmotic pumps releasing PNC-28 at a rate of 0.25 μl/hr
Result:	No ascites was seen in the PNC-28-treated animals. strongly effective in inhibiting this particular tumor.

Animal Model:	Athymic Nu/Nu mice (7–8 weeks, 22–24 g, injected i.p. with BMRPA1.Tuc3 cells)^[1]
Dosage:	1 mg/mouse, 10 mg/mouse and 20 mg/mouse
Administration:	When the tumors reached sizes from 40 to 260 mg/mouse, mini-osmotic pumps were implanted s.c. that released, over a period of 14 days
Result:	Resulted in a significant level of tumor growth inhibition in a dose-related manner.

References

[1] Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006 Oct 1;119(7):1577-85. DOI:10.1002/ijc.22029
[2] Kelley A. Sookraj. QS304. Novel p53-Derived Peptide Induces Rapid Human Pancreatic Cancer Cell Death. 2008, 144(2), 1.

Supplier

Hangzhou Peptidego Biotech Co.,Ltd.

Telephone0571-87213919

Websitehttp://www.peptidego.com

Hangzhou Sinoda Pharmaceutical Technology Co. LTD

Telephone0571-87213919 17306812703

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1355681/0.htm

Nanjing Typeptide Biotechnology Co.,Ltd.

Telephone 19941518170

Websitehttps://www.typeptide.com

PROMPT×

PROMPT
The What'sApp is temporarily not supported in mainland China

Cancel

Determine

Send Inquriy